View in EDS

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Saved in:
Bibliographic Details
Title: Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Authors: Jungova A; Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic. Electronic address: jungovaa@fnplzen.cz., Stork M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Spicka I; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic., Radocha J; 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Minarik J; Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic., Pavlicek P; Department of Internal Medicine and Haematology 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Mihalyova J; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Straub J; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic., Maisnar V; 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Pika T; Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic., Dekojova T; Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic., Soukup J; Department of Internal Medicine and Haematology 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Popkova T; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Mensikova K; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Sedlák F; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic., Pospiskova J; 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Boichuk I; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Krhovska P; Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic., Stopka T; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic., Jindra P; Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic., Jelínek T; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Knechtová Z; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Capounova V; 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Latal V; Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic., Muronova L; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Heindorfer A; Department of Hematology, Liberec Regional Hospital, Liberec, Czech Republic., Ullrychova J; Department of Hematology, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic., Sykora M; Department of Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic., Kessler P; Department of Hematology, Hospital Pelhrimov, Pelhrimov, Czech Republic., Hajek R; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hemato-Oncology, Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Apr; Vol. 26 (4), pp. e470-e482. Date of Electronic Publication: 2025 Nov 02.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2152-2669
DOI:10.1016/j.clml.2025.10.022